Picture loading failed.

Anti-ERBB2 therapeutic antibody (Pre-made Margetuximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-335-1mg 1mg 3090
GMP-Bios-ab-335-10mg 10mg 21890
GMP-Bios-ab-335-100mg 100mg 148000
GMP-Bios-ab-335-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-ERBB2 therapeutic antibody (Pre-made Margetuximab biosimilar,Whole mAb)
INN Name Margetuximab
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesRaven biotechnologies;GC Pharma;Green Cross;MacroGenics;Merck Sharp & Dohme
Conditions ApprovedBreast cancer
Conditions ActiveGastric cancer;Oesophageal cancer
Conditions DiscontinuedBladder cancer;Non-small cell lung cancer;Ovarian cancer;Haematological malignancies;Solid tumours
Development Techna